Roth Capital Reaffirms Buy Rating for Dare Bioscience (NASDAQ:DARE)

Share on StockTwits

Roth Capital reaffirmed their buy rating on shares of Dare Bioscience (NASDAQ:DARE) in a report published on Sunday, AnalystRatings.com reports. The firm currently has a $4.00 price target on the biotechnology company’s stock.

A number of other research firms have also weighed in on DARE. Aegis reaffirmed a market perform rating and set a $5.00 price objective on shares of Dare Bioscience in a research report on Sunday. Brookline Capital Management began coverage on Dare Bioscience in a research report on Tuesday, April 28th. They set a buy rating and a $7.50 price objective on the stock. ValuEngine lowered Dare Bioscience from a buy rating to a hold rating in a research report on Wednesday, July 8th. Maxim Group reaffirmed a buy rating and set a $3.00 price objective on shares of Dare Bioscience in a research report on Thursday, June 18th. Finally, Dawson James reaffirmed a buy rating and set a $3.00 price objective on shares of Dare Bioscience in a research report on Sunday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $4.50.

NASDAQ:DARE opened at $1.52 on Friday. The stock’s fifty day moving average is $1.02 and its two-hundred day moving average is $1.06. Dare Bioscience has a 52 week low of $0.69 and a 52 week high of $2.22. The stock has a market capitalization of $26.92 million, a price-to-earnings ratio of -1.73 and a beta of 1.82.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.16. As a group, equities analysts predict that Dare Bioscience will post -0.61 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Dare Bioscience stock. UBS Group AG bought a new stake in Dare Bioscience Inc (NASDAQ:DARE) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 38,502 shares of the biotechnology company’s stock, valued at approximately $32,000. UBS Group AG owned about 0.15% of Dare Bioscience at the end of the most recent reporting period. 3.50% of the stock is owned by institutional investors.

About Dare Bioscience

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

See Also: Stock Market – What is a circuit breaker?

Analyst Recommendations for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.